Could vitamin B3 help beat TB? new trial launches
NCT ID NCT07517445
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding nicotinamide (a form of vitamin B3) to a standard three-drug regimen can safely and effectively treat drug-susceptible pulmonary tuberculosis. About 165 adults with newly diagnosed TB will receive one of two doses of nicotinamide plus the standard drugs, or the standard drugs alone. The study measures how quickly the bacteria clear from sputum and monitors for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nicotinamide (vitamin B3) combined with bedaquiline, pretomanid, and linezolid
What this could lead to
If successful, this could lead to a shorter, more effective treatment regimen for drug-susceptible tuberculosis.
What could go wrong
This is an early phase 2 trial with only 165 participants, so results may not apply to everyone. The combination may cause side effects or not work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG SUSCEPTIBLE PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centre of Tuberculosis Research Innovation
NOT_YET_RECRUITINGCape Town, Western Cape, 7700, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
-
TASK Clinical Research Centre
RECRUITINGCape Town, Western Cape, 7530, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Aurum Institute Clinical Research Site - Pretoria
RECRUITINGPretoria, Gauteng, 87, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wits RHI - Shandukani Research
RECRUITINGJohannesburg, Gauteng, 2001, South Africa
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••